Welcome to the Podiatry Arena forums

You are currently viewing our podiatry forum as a guest which gives you limited access to view all podiatry discussions and access our other features. By joining our free global community of Podiatrists and other interested foot health care professionals you will have access to post podiatry topics (answer and ask questions), communicate privately with other members, upload content, view attachments, receive a weekly email update of new discussions, access other special features. Registered users do not get displayed the advertisements in posted messages. Registration is fast, simple and absolutely free so please, join our global Podiatry community today!

  1. Have you considered the Clinical Biomechanics Boot Camp Online, for taking it to the next level? See here for more.
    Dismiss Notice
Dismiss Notice
Have you considered the Clinical Biomechanics Boot Camp Online, for taking it to the next level? See here for more.
Dismiss Notice
Have you liked us on Facebook to get our updates? Please do. Click here for our Facebook page.
Dismiss Notice
Do you get the weekly newsletter that Podiatry Arena sends out to update everybody? If not, click here to organise this.

Botox for toe walking

Discussion in 'Pediatrics' started by NewsBot, Mar 6, 2013.

  1. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1

    Members do not see these Ads. Sign Up.
    Botulinum Toxin A Does Not Improve the Results of Cast Treatment for Idiopathic Toe-Walking: A Randomized Controlled Trial
    Pähr Engström, et al
    The Journal of Bone & Joint Surgery, Volume 95, Issue 5; March 06, 2013
     
  2. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
  3. Bug

    Bug Well-Known Member

    This is great and the biggest study out there on botox. Personally, have seen great results for children with ITW who are fully unable to get their feet to the ground but this is a good reminder that sometimes the simple casting gets the job done. One issue that isn't covered is the long term followup post 12 months.
     
  4. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
  5. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Botulinum Toxin Type A Injection for Spastic Equinovarus Foot in Children with Spastic Cerebral Palsy: Effects on Gait and Foot Pressure Distribution.
    Choi JY et al
    Yonsei Med J. 2016 Mar;57(2):496-504
     
  6. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Does Botulinum Toxin A Treatment Enhance the Walking Pattern in Idiopathic Toe-Walking?
    Satila H1 et al
    Neuropediatrics. 2016 Apr 18
     
  7. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Accelerated Multi-Modality Rehabilitation Protocol Combined with Botulinum Toxin-A Injection in Adult Idiopathic Toe Walking: Case Report
    Sibel Kibar, Ferdi Yavuz, Birol Balaban
    Year : 2016 | Month : June | Volume : 10 | Issue : 6 | Page : YD01 - YD03 An
     
  8. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Press Release:
    FDA Approves Botox (onabotulinumtoxinA) for Pediatric Patients with Lower Limb Spasticity, Excluding Spasticity Caused by Cerebral Palsy
    DUBLIN, Oct. 24, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental Biologics License Application (sBLA) for Botox for the treatment of pediatric patients (2 to 17 years of age) with lower limb spasticity, excluding spasticity caused by cerebral palsy (CP). This marks the 11th Botox therapeutic indication, having been approved for pediatric upper limb spasticity (ULS) earlier this year. Spasticity is a debilitating neurological condition involving muscle stiffness that can result in tight muscles in the upper and lower limbs, and can interfere with movement. The severity can range from mild to severe muscle stiffness.


    "Lower limb spasticity can impact many aspects of a child's life and have a drastic influence on their overall development and quality of life," said David Nicholson , Chief Research and Development Officer, Allergan. "This milestone will continue to support and advance care for children and their caregivers who may be struggling with lower limb spasticity. Here at Allergan, we look forward to continuing to highlight our unwavering attention to innovation and build on our 30-years of research and development efforts with Botox since FDA approval of blepharospasm and strabismus in 1989."

    The FDA approval is based on a Phase 3 study evaluating the safety and efficacy of BOTOX® in more than 300 pediatric patients aged two to 17 years old being treated for lower limb spasticity. While trial participants had cerebral palsy, the approved indication excludes lower limb spasticity caused by cerebral palsy due to marketing exclusivity by another company. These trials included a 12-week, double-blind study and a one-year open-label extension study.

    The approved recommended dose per treatment session is 4 Units per kilogram to 8 Units per kilogram divided among affected muscles of the lower limb. The total dose per treatment session in the lower limb should not exceed 8 Units per kilogram or 300 Units, whichever is lower. When treating both lower limbs or upper and lower limbs in combination, the total dose in pediatric patients should not exceed 10 Units per kilogram body weight or 340 Units, whichever is lower, in a 3-month interval.

    "Pediatric lower limb spasticity inhibits normal muscular movement and function and can result in delayed or impaired motor development, as well as difficulty with posture and positioning," said Mark Gormley, Jr. M.D., Pediatric Rehabilitation Medicine Specialist, Gillette Children's Specialty Healthcare-St. Paul. "BOTOX® has a well-established safety and efficacy profile, and supports children and adolescents successfully manage both their upper and lower limb spasticity."

    Allergan is committed to providing resources and services, such as the Botox Savings Program, to help ensure Botox is accessible and affordable to patients
     
  9. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    IncobotulinumtoxinA Injection for Treating Children with Idiopathic Toe Walking: A Retrospective Efficacy and Safety Study
    Mirko Filippetti et al
    Toxins 2022, 14(11), 792
     
Loading...

Share This Page